PPP1R21 function had not been studied except that a large scale affinity proteomics approach suggested an interaction with PIBF1 defective in Joubert syndrome. Our co-immunoprecipitation studies did not confirm this but in contrast defined the localization of PPP1R21 to the early endosome. Consistent with the subcellular expression pattern and the clinical phenotype exhibiting features of storage diseases, we found patient fibroblasts exhibited a delay in clearance of transferrin-488 while uptake was normal. In summary, we delineate a novel neurodevelopmental syndrome caused by biallelic PPP1R21 loss of function variants, and suggest a role of PPP1R21 within the endosomal sorting process or endosome maturation pathway.
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BACKGROUND
Increased utilization of next-generation sequencing (NGS), such as whole exome (WES) and whole genome sequencing (WGS) has enabled rapid expansion of our understanding of the genetic etiology of neurodevelopmental disease. Historically, diagnostic evaluation consisted of phenotype-driven genetic testing; however, this approach has limited efficacy for common and genetically heterogeneous phenotypes like developmental delay. The increased utilization of NGS-based testing, including exome analysis, has enabled a gene-and variant-driven approach to diagnosis and has greatly accelerated new syndrome and new disease gene discovery (Boycott et al., 2017; Chong et al., 2015) . Majority of the newly recognized disease genes have been identified in individuals with neurological disorders. The underlying molecular mechanisms for these disorders range from gene defects resulting in true brain malformations to causing degenerative disease.
Neurological deficits are also frequently observed with metabolic disorders where defective lipid, mucopolysaccharide or glycoprotein processing results in a specific subgroup of disease entities referred to as (lysosomal) storage disorders. The common clinical features of lysosomal storage disorders include coarse facial features and skeletal abnormalities, enlargement of liver and spleen, neurodevelopmental delay (mainly manifesting as neurodegenerative phenotype), lung and heart disease as well as hearing and visual impairment. More than 50 disease entities have been described to date and although individually very rare, together they represent a significant disease burden affecting approximately 1:5,000 individuals (Fuller, Meikle, & Hopwood, 2006) . Age of onset of symptoms varies from prenatally to adult age. Inheritance patterns are mostly autosomal-recessive and rarely, X-linked.
Lysosomes are the recycling centers of cells and degradation of macromolecules requires a number of enzyme-driven steps within the endosomal-autophagic-lysosomal system. Mechanistically, functional deficits in degradation pathways cause accumulation of such material within lysosomes as well as within the cytosol with toxic effects, eventually resulting in cell death. Most defective genes encode for enzymes, however defects have also been identified in genes encoding for proteins involved in transport processes or transmembrane proteins (Bennett & Hofmann, 1999; Fuller et al., 2006; Parkinson-Lawrence et al., 2010) . Lysosomal degradation of cellular material can be accomplished via different pathways, including endosomal degradation where late endosomes fuse with lysosomes, including transient docking for content exchange (Platt, Boland, & van der Spoel, 2012) . Endosome maturation into late endosomes occurs after approximately 5-10 min of fusion with novel endocytic vesicles (Maxfield, 2014) . Early endosomes (EE) serve as a focal point of the endocytic pathway where internalized proteins and lipids are destined for recycling to the plasma membrane, for degradation in lysosomes or delivered to the trans-Golgi network and functional deficits have been shown to play a role in a number of human diseases often demonstrating a neurological phenotype such as Alzheimer's disease, Down syndrome, Lowe syndrome, and Huntington's disease (Jovic, Sharma, Rahajeng, & Caplan, 2010) .
Despite the progress made in recent years, substantial gaps remain in understanding the heterogeneity of clinical phenotypes of neurological disorders and the underlying molecular mechanisms.
Here, we report on six patients from four unrelated consanguineous families with similar neurological phenotype. We detected homozygous truncating variants in PPP1R21 (Protein Phosphatase 1, regulatory subunit 21) in the affected individuals by WES or WGS. In parallel to our study, PPP1R21 loss of function alleles have been identified in three individuals with a similar syndromic neurodevelopmental phenotype, however no functional studies to understand the underlying patho-mechanism and PPP1R21 protein function had been performed and PPP1R21 function had remained elusive. Here, we now suggest a role for PPP1R21 within the endo-lysosomal compartment and propose PPP1R21 loss of function results in a mild disturbance of endosome function.
METHODS

Ethics statement and family ascertainment
The study was conducted in accordance with the protocol approved 
Whole exome and whole genome sequencing and subsequent analyses
Peripheral blood samples were collected from available members of the four families and genomic DNA was extracted using standard protocol. WES was performed either at Baylor Genetics Laboratories using VCRome v3 in-solution exome probes followed by sequencing on Illumina HiSeq 2500 instrument (Family 1, subject II-6), using kit Agilent SureSelect Human All Exon v5 and sequencing on Illumina HiSeq 2500 at University of Geneva (Family 1, subject II-5), using Agilent Sure select V6 with subsequent sequencing on a HiSeq machine at Novogene LTD Hong Kong for Nijmegen samples (Family 3, subject V:4) or using Agilent Sureselect QXT CREv1 kit, followed by sequencing on Illumina NextSeq500 at Victorian Clinical Genetics Services (Family 4). Further, OmniExpress 750K array was used in Family 2 for genome-wide homozygosity mapping using DNA from six family members at Sidra Medical & Research Center in Qatar ( Figure 1A ) which showed three regions of homozygosity co-segregating with the disease (Supp. Figure S1 ). Subsequently, DNA sample from individual II-3 was subjected to WGS to a mean coverage of 30× on the Illumina HiSeq X platform and data was analyzed for potential pathogenic variants within the three regions of homozygosity.
Sequencing data from each family was independently analyzed by respective diagnostic or research laboratories. Variants with >1% allele frequency in public SNP databases were removed from further analysis and the remaining variants were prioritized based on genetic evidence including variant rarity (e.g., novel variant), allele transmission (e.g., biallelic variants), predicted variant severity, and phenotype overlap between reported genetic disorders and the patient phenotypes. Possible causal variants in known disease genes that could explain patient's phenotype were not detected in any subject. To further explore the genetic basis of disease in these families, we investigated all rare deleterious variants that are in nondisease genes especially homozygous variants because of consanguinity in the families and apparently recessive mode of inheritance ( Figure 1A ). Follow up confirmation and co-segregation analyses for putative pathogenic variants were performed using Sanger sequencing for families 1-3 following standard protocols. Primer sequences can be found in a supplemental table in the supplemental material. Identified PPP1R21 variants were submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).
Immunofluorescence and cell culture studies
Immunofluorescence and cell culture analyses were performed as previously described (Schmidts et al., 2015) . Briefly, IMCD3, hTERT-RPE, SH-SY5Y cells and patient as well as control fibroblasts were cultured in DMEM-F12 medium with 5% FBS under standard conditions. For ciliation experiments, cells were serum starved for 24 hr. Primary anti- 
Transferrin assay
Patient fibroblasts and control fibroblasts from an age matched healthy individual were grown under standard conditions and serum ; axial T2-w image demonstrating slight prominence to the supratentorial ventricular system with increased T2 hyperintensity returned from the bilateral posterior centra semiovale. Image 5; demonstrates irregular outline to the bodies of both lateral ventricles in addition to the increased T2 hyperintensity returned from the periventricular white matter. Image 6; sagittal T1-w midline image again demonstrating thinning and foreshortening to the body of the corpus callosum. Family 3: Image 7; axial T2-w image demonstrates prominence to the bodies of the lateral ventricles with generous extra-axial CSF spaces with bilateral and symmetric underopercularization. Image 8; axial T2-w image shows a slightly irregular outline to the bodies of both slightly prominent lateral ventricles. Image 9; sagittal T2-w midline image demonstrates thinning and foreshortening of the corpus callosum. Family 4: images 10-12 obtained from affected individual IV.1 showing abnormally deep and box-like Sylvian fissures, diffuse reduction in cerebral volume, particularly the deep white matter signs of dysmyelination, diffuse reduction in the brainstem and vermian volume (molar tooth sign in image 11) and dysmorphic appearance of the corpus callosum and brainstem. (C) Schematic representation of the PPP1R21 gene, its predicted protein product, and locations of the pathogenic variants. Introns, exons, and untranslated regions of the PPP1R21 gene are shown by a horizontal line, vertical thick bars, and thin gray bars, respectively. Exon numbering and variant nomenclature is based on RefSeq accession number NM_ NM_001135629.2 for cDNA and NP_001129101.1 for protein starved for 3 hr before start of the experiment. Cells were incubated in medium containing transferrin-Alexa-Fluor-488 conjugate 1:1,000 (Invitrogen/ThermoFisher, USA) and fixed in 4% PFA after 5, 10, and 30 min of incubation. Cells were then mounted in vectashield containing DAPI and images taken using a Zeiss Axiovert Apotome microscope.
For washout/chase, cells were repetitively washed and re-incubated in fresh medium containing unlabeled transferrin 1:200 every 20 min and fixed in 4% PFA after 1 and 2 hr washout/chase, mounted in vectashield containing DAPI and images taken using a Zeiss Axiovert Apotome microscope.
q-PCR
PPP1R21 mRNA-quantification in fibroblasts carrying PPP1R21 p.Leu536Phefs*7 in a homozygous manner versus fibroblasts from a healthy control individual was performed using total RNA and q-PCR performed using SYBR-Green (Qiagen, Germantown, USA) according to the manufacturer's protocol. PPP1R21 levels were normalized to GAPDH levels. Statistical analysis was performed using Student's t-test.
RESULTS
Clinical findings
Salient clinical features of six subjects from the four study families are provided in Table 1 Additional common features among both siblings were feeding difficulties, delayed bone age, pectus carinatum, and mild scoliosis. The older subject (II-3) was diagnosed with ASD by echocardiogram whereas the younger subject (II-4) presented to the hospital at the age of 4 years with fever and opsoclonus/myoclonus which settled after steroids administration. MRI studies demonstrated irregular outline to the bodies of both lateral ventricles in addition to the increased T2 hyperintensity returned from the periventricular white matter, and thinning and foreshortening to the body of the corpus callosum. Karyotyping and array CGH studies performed in the older subject were normal.
The proband (V:4) from Family 3 is a female born as result of the first pregnancy to first cousin Iranian parents. Her dizygotic twin sister is healthy. The proband was referred for genetic testing at the age of 8 months due to severe global developmental delays with fronto-temporal pronounced thin cerebral cortex with enlarged outer liquor spaces and enlarged lateral ventricles, thin corpus callosum, and hypoplasia/atrophy of the optic nerve on brain MRI. Additional clinical features included hypotonia, respiratory distress, slightly coarse facial features, and hepatosplenomegaly. Family history showed that her deceased first cousin (V:1) had a similar clinical presentation including developmental delay/intellectual disability (IQ below 60), and ophthalmic features (strabismus, decreased visual acuity, and was blind when she passed away at the age of 12 years). The proband as well as the deceased affected cousin were not able to sit or walk. Additionally, hypothyroidism was noted in both affected individuals as well as some healthy family members. Prior genetic testing was not performed in this family.
The proband from Family 4 is the first child born to consanguineous Arab parents following a normal pregnancy. He was admitted at the age of 16 months to pediatric intensive care with an episode of decreased consciousness and hypothermia, on a background of global developmental delay, hypotonia, and feeding difficulties. He had plagiocephaly, torticollis, slightly coarse facial features, and undescended testes. He was smiling responsively, but unable to roll. MRI of the brain demonstrated abnormally deep and box-like Sylvian fissures, diffuse reduction in cerebral volume, particularly the deep white matter, diffuse reduction in the brainstem and vermian volume, and dysmorphic appearance of the corpus callosum and brainstem.
Identification of disease-causing variants
In order to establish the underlying genetic cause, we performed whole exome and whole genome sequencing in these four families. Analyses of WES and WGS data showed the proband in each of the four families this study (n = 6) as well as of three individuals reported in parallel to our study by Suleiman et al. (2018) are displayed in Table 1 . PPP1R21 variants identified to date are shown in Table 2 .
Gene structure of PPP1R21
PPP1R21 resides on the short arm of chromosome 2 (2p16.3) and 
Protein structure and expression pattern of PPP1R21
The PPP1R21 protein belongs to a family of predicted coiled-coil domain containing proteins and its function has not been studied in depth to date and no functional domains have been described. We queried the NCBI database of nonredundant protein sequences (NCBI BLAST: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) using the longest isoform (NP_001129101.1) of PPP1R21 and found two putative conserved domains within PPP1R21; an N-terminal KLRAQ domain, and a C-terminal TTKRSYEDQ domain ( Figure 1C ). The predicted 100 amino acid long KLRAQ domain is encoded by residues 11-111 and contains a characteristic KLRAQ sequence-motif. The 500 amino acids long C-terminal TTKRSYEDQ domain is encoded by residues 255-771 and has a characteristic TTKRSYEDQ sequencemotif ( Figure 1C ). Both domains are conserved from nematodes to humans but their molecular function(s) are yet to be discovered.
The Human Protein Atlas database (https://www.proteinatlas.org)
lists that PPP1R21 mRNA is expressed in a variety of tissues including brain, endocrine, lungs, liver, heart, pancreas, spleen, and gastrointestinal tract. At the protein level, the strongest expression appears to be in cerebellum, esophagus, pancreas, thyroid and parathyroid glands, among others (Supp. Figure S2 ). We subsequently confirmed cortical expression of PPP1R21 during murine development by performing immunofluorescence analysis on mouse E16 frozen cortex sections using HPA036792, Atlas antibodies, Sweden) (Supp. Figure S3 ).
Subcellular localization of PPP1R21
Small cerebellum noted on the MRI and the phenotype observed in some individuals with biallelic PPP1R21 loss of function mutations shows partially overlapping features with Joubert syndrome including ataxic wide-based gait; further large-scale affinity-MS proteomics analyses has previously suggested PPP1R21 to interact with a known Joubert syndrome gene, PIBF1 (Huttlin et al., 2015; Wheway et al., 2015b) . This prompted us to next test the putative protein-protein interaction between PPP1R21 and PIBF1 by co-immunoprecipitation.
Our tests could not confirm the interaction however (Supp. Figure   S4 and Supp. Figure S5 ) and subcellular immunofluorescence studies in several cell lines such as hTERT-RPE (retinal pigment epithelium), IMCD3 (inner medullary collecting duct), and the neuronal cell line SH-SY5Y did not show ciliary or basal body or centrosomal PPP1R21 localization (Supp. Figure S6 , -acetylated tubulin (T7451, clone 6-11-B) Sigma 1:500, -PPP1R21). Rather, we observed a vesicular staining pattern within the cytosol of all tested cell lines which prompted us to further investigate the nature of these vesicles by performing co-staining with antibodies for Golgi and endosomal marker proteins. We did not detect co-localization of PPP1R21 with the two Golgi markers that we tested ( -58K; ab27043 from Abcam, and -GM130; ab169276, Abcam). However, we found a nearly complete co-localization of PPP1R21 with the early endosome marker EEA1
(ab70521, mouse monoclonal, Abcam) using two different PPP1R21
antibodies, HPA036791 and HPA036792 (rabbit polyclonal, Atlas antibodies, Sweden) (Figure 2A ).
PPP1R21 expression is missing in patient fibroblasts
qPCR analyses revealed that PPP1R21 mRNA levels are greatly reduced in PPP1R21 deficient fibroblasts compared to control fibroblasts (Supp. Figure S7 ) but not completely absent. We, therefore, Figure S8 ).
Increased number of myelin figures in PPP1R21 deficient fibroblasts confirming mild endo-lysosomal dysfunction
Our immunofluorescence data as well as the transferrin uptake and clearance assay suggested PPP1R21 locates to the early endosome and that patient fibroblasts exhibit mild endo-lysosomal dysfunction. 
DISCUSSION
This study identified four previously unreported homozygous truncating alleles of PPP1R21 co-segregating in four independent consanguineous families with affected individuals exhibiting overlapping clinical features. Consistent with our findings, a female subject homozygous for a PPP1R21 null allele was recently described within a larger cohort of developmental delay cases (Anazi et al., 2017) . Her reported clinical presentation was very similar to what we observed in families 1-4 in our study including slightly coarsened dysmorphic facial features, severe global developmental delays, hypotonia, respiratory distress, feeding difficulties, hepatomegaly, and vision impairment.
During preparation of this manuscript, two additional subjects with homozygous putative PPP1R21 null alleles have been described (Suleiman et al., 2018) . We have summarized common clinical features observed among all nine subjects (six from this study and three previously reported (Anazi et al., 2017; Suleiman et al., 2018) in Table 1: most commonly observed features include hypotonia (9/9), severe global developmental delays (9/9), dysmorphic mildly coarsened facial features (9/9), vision impairment and/or nystagmus (8/9), respiratory problems (n = 7/9), feeding difficulties (n = 9/9), cardiac concerns We observed 1-2 myelin bodies per vision field (arrows). These figures were not observed in two fibroblast control cell lines cultured in parallel. Scale bar: 500 nm (n = 4/9), and hepato/hepatosplenomegaly (n = 3/7; Table 1 ). Common findings on MRI of the brain include prominent and slightly dysmorphic ventricular system with irregular outline to the bodies of the lateral ventricles reminiscent of PVL (periventricular leukomalacia) and consistent with loss of white matter ( Figure 1B and Table 1 ). There is some increased T2 hyperintensity returned from the deep white matter in all cases (where images were available). Further, generous extraaxial CSF spaces with bilateral and symmetric underopercularization as well as slight foreshortening and thinning of the corpus callosum was noted as well as cerebellar hypoplasia in some but not all cases.
PPP1R21 is an evolutionarily conserved protein (Supp. Figure   S9 ) with an undiscovered function and no investigations toward understanding the underlying patho-mechanism had been performed.
This prompted us to perform functional analysis to gain insight into the physiological role of PPP1R21 and to identify possible disease mechanism for the observed PPP1R21-associated phenotype. Consistent with the severe neurodevelopmental phenotype observed, our immunofluorescence studies confirmed PPP1R21 expression within the developing mouse cortex (Supp. Figure S3) . A large-scale proteomics study had previously suggested PPP1R21 may interact with PIBF1, a protein found to be defective in some individuals with Joubert syndrome (Huttlin et al., 2015; Wheway et al., 2015a) . However, our co-immunoprecipitation analyses did not confirm the suggested interaction (Supp. Figure S4 ). Rather, using two different antibodies, we observed nearly complete co-localization of PPP1R21 with the early endosome marker EEA1 (Figure 2A ) and transferrin-488 uptake and clearance assays (Figure 3 ) suggested a mild endo-lysosomal functional defect. We found that although there was no difference of transferrin uptake between control and patient fibroblasts, its clearance was mildly but statistically significantly delayed in the PPP1R21 mutant cells after 2 hr of repetitive washes with medium containing unlabeled transferrin ("chase"). This could indicate a mild endosome maturation or fusion defect or could result from a trafficking defect back toward the plasma membrane. Such impaired proteolipid protein trafficking has been previously described to result from cathepsin D deficiency where phenotypically delayed central nervous system myelination was observed (Guo et al., 2018; Steinfeld et al., 2006) and hypomyelination was also noted in the brain MRI scans in Family 1 described here. The dynamics of the endocytic pathways are governed by several Rab family members with Rab 5 playing a major role in the early endosome traffic (Barbieri, Roberts, Mukhopadhyay, & Stahl, 1996; Murray, Panaretou, Stenmark, Miaczynska, & Backer, 2002) . Some phenotypic features observed in the affected families may also directly result from Protein Phosphatase 1 (PP1) dysfunction. PP1 is a major serine/threonine phosphatase with an immense diversity of functions, including fundamental processes such as glycogen metabolism (Munro, Cuthbertson, Cunningham, Sales, & Cohen, 2002) , cell cycle regulation, and regulation of centriole duplication (Peel et al., 2017) , apoptosis (Garcia et al., 2003) , and PP1 is expressed during development in murine brains (Collins & Sim, 1998) . PP1 consists of a catalytic subunit (PPP1CA) and a high number of regulatory subunit determining the subcellular localization of PP1 and regulating its function. Future work will be required to further investigate this area.
Although previously published large scale proteomics data suggested an interaction with the Joubert protein PIBF1, patient phenotype did not match Joubert syndrome or related ciliopathies and our co-immunoprecipitation studies and the subcellular localization to early endosomes in several cell lines points against a role within the Joubert syndrome protein network. Rather, our results point toward a defect within the endosomal-lysosomal compartment, as it has been previously suggested for other neurodegenerative diseases in humans, resulting in an endocytic defects or impaired clearance of certain molecules from this compartment. For example, a phenotype somewhat resembling the phenotype we observe with PPP1R21 loss of function including coarse face, neurodevelopmental delay, and cerebellar atrophy was described to result from SNX14 (sorting nexin 14)
loss of function mutations (Akizu et al., 2015; Thomas et al., 2014) .
SNX proteins are known to play a role in endosomal cargo sorting and SNX14 was shown to be essential for fusion of late endosome/autophagosomes with lysosomal vesicles in fibroblasts as well as neuronal precursor cells from individuals (Akizu et al., 2015) .
In conclusion, we propose recessive PPP1R21 loss of function vari- proper functioning of the early endosome compartment. Future studies including appropriate animal models are warranted to understand the precise molecular mechanism that leads to PPP1R21-associated neurodevelopmental phenotype.
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